3SBio | ApexOnco - Clinical Trials news and analysis

x

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Deals

20 May 2025

Pfizer bets big on a bispecific

The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.

Subscribe to 3SBio